Company, Position & Person Profile

3i Group plc

Healthcare General Partner, 3i Ventures

. Heidrick & Struggles advises the company on the basis of an exclusive consulting

assignment. The following details are for your personal information and should be kept

confidential.

The Company

3i Group is a world leader in private equity and venture capital. The firm is active across all stages of funding. From early-stage venture capital to growth capital and buyouts, the U.K.-headquartered firm invests $1.5bn a year globally in industries across a variety of sectors.

3i has been in business for over 60 years. In the last five years alone, 3i has achieved more than 500 portfolio exits and has listed 43 companies via initial public offerings on 12 international exchanges. The firm is traded on the London Stock Exchange and is part of the FTSE 100 index.

3i’s purpose is to substantially increase the value of the companies in which it invests and then to realize this value, both for the firm and its partners, through exit events and stock market listings. Their track record demonstrates that they have consistently achieved this, even in the toughest of bear markets.

3i's international relationship network is unique. Their team of over 300 investment professionals spans three continents, linking them to a wealth of corporate contacts and industry experts. This gives 3i both a local and global view of industry trends. The breadth of the firm’s network ensures that they are able to bring together the best team, with the right experience and relationships for each investment opportunity. It also means 3i has the scale, the agility and the

Company, Position & Person profile 3i Group plc 2

talent needed to deliver even the most challenging deals.

3i Ventures

3i Ventures is one of three dedicated funds within 3i Group; the other two are its Buyout Fund and Growth Fund. With 3i Group as its sole limited partner, fundraising risks are limited, which we believe is a tremendous benefit to its platform. Currently there are 18 investment partners in 3i’s US Venture group, with two based in Menlo Park, CA and three in Boston, MA.

Healthcare Sector Focus

3i’s longstanding focus on healthcare spans across domains from services to pharmaceuticals and biotechnology, as well as in medical devices. The firm has financed some of the best-known names in healthcare, and their portfolio of prior, current, and pending investments now is in excess of 300 companies (a list of investments is attached at the end of this position specification). The focus of U.S. venture capital investing is primarily in patent protected intellectual property intensive investments, such as those in devices, pharmaceuticals, and biotechnology. Investments where operational excellence is necessary will also be considered, such as those in healthcare services. The U.S. venture capital investing in healthcare is done from two offices, one in Menlo Park and the other in Boston. S/he will work closely not only with the west coast team but also with the 3i team worldwide to ensure consistency of approach and best ideas/ practices sharing.

Company, Position & Person profile 3i Group plc 3

The Opportunity3i has brought on new leadership within the last two years, naming Philip Yea as CEO and Jo Taylor as Managing Partner, Venture Capital. The firm has also recently made a renewed commitment to the U.S. market, which has led to some organizational and personnel changes, including the globalization of its investment approach and its structure. It has also recently named two people to lead its growth capital business in the U.S., which is a new effort in this region. The firm views the senior-level hire in healthcare, as well as an anticipated senior hires in its technology practice, as important steps in finalizing the configuration of the U.S. business.

The Position

TITLE: General Partner, Healthcare

LOCATION: Menlo Park, California

Specific Responsibilities

This position will develop an investment point-of-view around opportunities in healthcare across the various domains. The Partner will have significant responsibility in creating a framework that characterizes the greatest opportunity for 3i. In addition, partnership responsibilities include fiduciary duty in the context of current and future investments and managing them to best outcome. This person will be responsible for

Company, Position & Person profile 3i Group plc 4

the full range of investment activities, including sourcing, evaluating, negotiating, closing, monitoring and exiting of investments.

Specific responsibilities will therefore include:

Refine a strategic plan for healthcare investing in emerging companies with areas of emphasis

Successfully identify, examine, structure, and invest in venture healthcare investments

Monitor, manage, and optimize portfolio investments to highest returns

Build and advance 3i’s brand equity in the United States with regard to healthcare investing

Mentor, develop, and when appropriate identify and recruit members of the healthcare venture team so as to expand the franchise to the available market available opportunity in the United States

Perform rigorous fiduciary duty in all matters related to 3i and the portfolio

The PersonQualifications & Experience

Excellent technical credentials, such as a M.D., Ph.D. or a Masters or Bachelor in science; a M.B.A. would be beneficial, but not required.

Over 10 years of investment or other relevant experience with recognized market and industry leading institutions.

A demonstrated investment track record of successful healthcare investments

Company, Position & Person profile 3i Group plc 5

Strong history of independent deal origination and evidence of a high quality network of contacts and reputation in the market.

Demonstration of the management of technical risk is critical, as well as the avoidance of infatuation with technically intriguing but commercially unviable products.

Ability to work effectively across any team – the partnership, the deal team and the wider 3i network.

International experience preferred, but not required.

Experience serving on a variety of boards.

Proven analytical and deal-structuring skills.

Behavioral Competencies

Highly motivated to succeed and achieve superior performance.

Collegial and partnership-oriented.

Excellent business judgment.

Able to engage in open discussion, and be receptive to the input of others in the context of team decision-making.

Personal presence & communication skills as a component of influencing/leading decisions made by Boards of Directors.

Ability to gain respect quickly and to work well within the 3i culture of integrity, intelligence, hard work and partnership.

Desire to work and succeed in a visible and accountable environment.

Company, Position & Person profile 3i Group plc 6

Entrepreneurial desire to roll-up sleeves and continue building the portfolio and the firm.

Superior time and project management skills in the context of multi-tasking against deadlines.

Inculcate a performance culture that encourages thoughtful risk-taking and patience for market success and profitable growth.

Excels as an ambassador for 3i and in so doing builds corporate brand equity.

Impeccable personal and business ethics.

Strong leadership skills and executive presence. Highly engaging personality to lead, manage, and inspire others.

Willingness to travel domestically and internationally.

Company, Position & Person profile 3i Group plc 7

Heidrick & Struggles Contacts Richard N. Eidinger, M.DSenior Partnerdirect line +1 213 237 6287cell +1 310 717 6925e-mail reidinger@heidrick.com

Amy BottomsSenior Associatedirect line +1 360 779 7571e-mail abottoms@heidrick.com

Diane BradyExecutive Assistantdirect line +1 213 237 6287e-mail dbrady@heidrick.com

Heidrick & Struggles633 West Fifth Street, Suite 3300telephone +1 213 625 8811facsimile +1 213 694 2829www.heidrick.com

Company, Position & Person profile 3i Group plc 8

Appendix3i Healthcare Investments – Prior, Current & Pending Investments

Recent Healthcare Transactions

Company Business Description

Region Deal Size

Transmedics Medtech US $30 Million

Microsulis Microwave Ablation

UK ₤ 45 Million

Smallbone Innovations

Medical Device US $ 42 Million

Endosense Medical Device Switzerland $20 Million

Comprehensive Transaction List

3F Therapeutics, Inc., 4SC AG (DB:VSC), Able Systems Corporation, Acal plc (LSE:ACL), Acambis plc (LSE:ACM), Actelion Ltd. (SWX:ATLN), Adprotech Ltd., Aegis Analytical Corporation, Alderwoods UK, Alliance Medical Ltd., Amaxa Biosystems GmbH, Amgen Inc. (NasdaqNM:AMGN), Amoebics, Amphora Discovery Corporation, Amura Ltd., Amylin Pharmaceuticals Inc. (NasdaqNM:AMLN), Andreas Pein Medizintechnik GmbH, Aneo AB, AorTech International plc (AIM:AOR), ApaTech Ltd., Apovia AG, Aquaculture Vaccines Ltd., Ardana plc (LSE:ARA), Arexis AB, Argenta Discovery Ltd., Arpida (SWX:ARPN), Arrow Therapeutics Ltd., Artemis Pharmaceuticals GmbH, Asac Pharma, Asia Renal Care, AstaCarotene AB, Axxima Pharmaceuticals AG, B.R.A.H.M.S. Diagnostica GmbH, Betapharm Arzneimittel GmbH, BetterCare Limited, BioAlliance Pharma (ENXTPA:BIO), Biocompatibles International plc (LSE:BII), BioFocus DPI, Biofrontera AG, Biomade, Biopolis SpA, Bioquell plc (LSE:BQE), Biosearch Italia SpA, Bioserv AG, BioShape AG, Biosurface Pharma, BioTul Bio Instruments AG, Biovation, Ltd., Biovector

Company, Position & Person profile 3i Group plc 9

Therapeutics SA, Blease Medical Holdings Limited, Bradford Particle Desig, plc, BusinessHealth Group Ltd., Cambridge Antibody Technology Group plc (LSE:CAT), Cambridge Drug Discovery Holdings Ltd., Cambridge Genetics Limited, Care Principles Ltd., Carema Vård och Omsorg AB, Caretech Community Services Ltd., Carmel Pharma, Cascade Biochem Ltd., Castlebeck Care Holdings Ltd., Cell Analysis Ltd, CellaVision AB, Cenes Pharmaceuticals plc (AIM:CEN), Cerebrus Pharmaceuticals Limited, Ceuta Healthcare Ltd., Chiltern Invadex Ltd., Chimeric Therapies, Chiron Viagene, Inc. , Chiroscience Group plc (United Kingdom), Clínica Baviera, S.A., Cobra Therapeutics Ltd., Combinature Biopharm, Complete Case Management Holdings Limited, Core Group plc, Corin Group plc (LSE:CRG), Covidence GmbH, COX Analytical Systems, Craneware Ltd., Crucell NV (ENXTAM:CRXL), Curasan AG (DB:CUR), CyberGene AB, Cybergene SA, Cygnet Health Care Ltd., Cytocell Technologies Limited, DCC plc (ISE:DCC), Cytyc Corporatoin (NASDAQ: CYTC), deNovis Inc., Dentallabor Bandulet GmbH, Dextra Laboratories Ltd, Diagnology Limited, Domantis Limited, Doxa Certex, DrugAbuse Sciences Inc., e2v Technologies plc (LSE:E2V), EiRx Therapeutics (AIM:ERX), Elaiapharm S.A., elbion AG, Embrex, Endocrine Pharmaceuticals Ltd., Endosense SA, EndoSpine Ltd., Entigen Corporation, Eos Biotechnology, Inc., Epigenomics AG (DB:ECX), Eskuell AG, Evans Healthcare Ltd, Evolutec Group plc (AIM:EVC), Evotec Neurosciences GmbH, Farrow House Limited, Febit AG, Fluorochem Ltd, Gant Company AB (OM:GANT), Gendaq Ltd., Gendel Ltd., GeneScan Europe AG (DB:GEP1), Genesto A/S, Genome Express, GenPat77 Pharmacogenetics AG, GenPharmTox BioTech AG, Gensia Pharmaceuticals, Genta Inc. (NasdaqNM:GNTA), Geron Bio-Med, Geron Corporation (NasdaqNM:GERN), Gilead Sciences Inc. (NasdaqNM:GILD), Graffinity Pharmaceuticals AG, Grandis Biotech GmbH, Green Corns Limited, Gresham Scientific Instruments, Grupo Ballesol, Gyros Aktiebolag, Gyrus Group plc (LSE:GYG), Healthcall, Healthcare Scotland Ltd., Hint-Els Dentacad System GmbH, HOSPOR-Hospitais Portugueses, S.A., HumanOptics AG, Hutton & Co. (Ship Chandlers) Ltd, Hybrand Ltd, Id pharma GmbH, IDEA AG, IEP GmbH, Igeneon AG, Immatics Biotechnologies AG, Immunodiagnostic Systems Holdings plc, IMTEC Immundiagnostika GmbH, In4tek Ltd., Indigo Photonics Ltd., INNOVISION

Company, Position & Person profile 3i Group plc 10

A/S, Inpharmatica Ltd., Integrated Dental Holdings plc, Intercern Clinical Research Networks, Intercern Holdings Ltd., Intercytex Ltd. (AIM:ICX), IoDP Medical Imaging Research, IsoTis NV, IsoTis Orthobiologics (SWX:ISON), James Hull Associates, Jerini AG (DB:JI4), Key Organics Limited, KREATECH Biotechnology BV, Kronans Droghandel AB, KuDOS Pharmaceuticals Limited, Laurel Management Services Ltd., LGC Limited, Lichtwer Pharma AG, Ligand Pharmaceuticals (NASDAQ: LGND)MAP Medical Technologies Oy, Matrix MicroScience, MBT Munich Biotechnology AG, Meconic Plc (United Kingdom), Medeval Ltd., Medimod Research Institute GmbH, Medisense, Memorec Stoffel GmbH, Meristem Therapeutics, Merivaara, Metris Therapeutics Ltd., Micap Ltd. (AIM:MIC), Micromet, Inc. (NasdaqNM:MITI), Microsulis Medical Limited, Migenix Inc. (TSX:MGI), Millbrook Industries Limited, Mitokor, Inc, mNemoscience GmbH, Molecular Engines Laboratories, Molecular Staging, Inc., Mölnlycke Health Care AB, Montebello, Morphochem AG, Morphochem, Inc., Morphosys AG (DB:MOR), Nadag AG, Nanogate Technology GmbH, Nature's Store Ltd., Nektar Therapeutics (NasdaqNM:NKTR), NeoGuide Systems, Inc., NeoPharma AB, Neoventa Medical AB, Nervation Ltd., Nestor Healthcare Group plc (LSE:NSR), Neurocrine Biosciences Inc. (NasdaqNM:NBIX), Neurotech S.A., Neutec Pharma plc (AIM:NTP), Newron Pharmaceuticals SpA, Nexan PLC, Nova Science Ltd, Novexel SA, Novuspharma SpA, Nycomed Pharma AS, Onyvax Ltd., Ortivus AB (OM:ORTI B), Oxagen Limited, Oxford Asymmetry International, Oxford GlycoSciences Plc, Oxfordshire BiotechNet Ltd, PAION AG (DB:PA8), PaperPak Group, Patientline plc (LSE:PTL), PD Services Limited, Penlon Limited, Peptor Ltd., PerSeptive Biosystems, Personal Chemistry, Peter Black Pharmaceuticals Ltd., Pets at Home, Pharmaceutical Profiles Ltd., Pharmacia & Upjohn - CNS Research Centre, Pharmagene plc, Phase 1 Clinical Trials Unit Ltd, Phoqus Group plc (AIM:PQS), Physiomics plc (AIM:PYC), Physiotools Oy, Picis, Inc., Plethora Solutions Holdings PLC (AIM:PLE), Poggo Group, Polymer Laboratories Ltd., PPL Therapeutics plc, Practice Resource Systems, ProCorde GmbH, Profile Therapeutics plc, Prolifix, Ltd., ProStrakan Group plc (LSE:PSK), PULSION Medical Systems AG (DB:PUS), Q-One Biotech Ltd., Quadrant Healthcare Plc (United Kingdom), Redcliffe Magtronics, Residential Care Group, The, RiboTargets Holdings plc, Robinson Healthcare, Santhera Pharmaceuticals AG, SBL

Company, Position & Person profile 3i Group plc 11

Vaccin AB, Scienion AG, Scientific Detectors Ltd, Scios Inc., Scottish Medicine Ltd., Sensa, SensAlyse Limited, Shire plc (LSE:SHP), SICOR Inc., SIRENADE Pharmaceuticals AG, Sloning BioTechnology, Small Bone Innovations, Inc., Smith & Nephew's UK and Republic of Ireland Cotton Wool division, Sosei Co. Ltd. (TSE:4565), Sosei R&D Ltd., SR-Instruments Oy, Sterix Limited, Subnet Oy, SunTech Medical Group, Ltd, Suomen Terveystalo Oyj, Swissray International Inc., Switch Biotech GmbH, Synaptica Ltd., Synomics Ltd., Synprotec Ltd, Synt:em S.A., Tayside Flow Technologies Limited, TCT International Plc, Temmler Beteiligungs GmbH, The Magstim Company Ltd, Tiani Medgraph GmbH, Tissuemed, TransMedics, Inc., Triage Data Networks, Inc., Trigen Holdings AG, Trinity Care plc., Ulthera Inc., Ultrafine, Valley Forge Pharmaceuticals, Inc., Vanguard Healthcare Solutions Ltd., vasopharm BIOTECH GmbH, Vendôme S.A., Vernalis Group Plc, Vernalis plc (LSE:VER), Véto Santé, Vicuron Pharmaceuticals Inc., Virofem Diagnostica GmbH, Voxar Limited, Wavelight Laser Technologie AG (DB:WLT), Westminster Healthcare Holdings Ltd., Westminster Healthcare, Priority Private Health Clinic Chain, WGP 1 Plc, Xenova Group plc, Xerion Pharmaceuticals GmbH, XTL Biopharmaceuticals Ltd. (LSE:XTL), YAbA, YTY Group, Zonare Medical Systems, Inc.

Company, Position & Person profile 3i Group plc 12